Cytomegalovirus Prophylaxis With Intravenous Polyvalent Immunoglobulin in High-Risk Renal Transplant Recipients

Transplantation Proceedings

Volumn 38, Issue 7, 2006, Pages 2324-2326

  Leroy, F ^a   Sechet, A ^a   Ayache, R Abou ^a   Thierry, A ^a   Belmouaz, S ^a   Desport, E ^a   Bauwens, M ^a   Bridoux, F ^a   Touchard, G ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE KIDNEY FAILURE; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; DRUG TOLERANCE; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; IMMUNOPROPHYLAXIS; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; PRIORITY JOURNAL; RASH; SEROLOGY; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; VEIN THROMBOSIS;

CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, INTRAVENOUS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33846115123     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.07.001     Document Type: Article

References (7)

1. Pouteil-Noble C., Ecochard R., Landrivon G., et al. Cytomegalovirus infection-an etiological factor for rejection?. A prospective study in 242 renal transplant recipients. Transplantation 55 (1993) 851
2. Snydman D.R., Werner B.G., Heinze-Lacey B., et al. Use of cytomegalovirus immune globulin to prevent CMV disease in renal-transplant recipients. N Engl J Med 317 (1987) 1049
3. Conti D.J., Freed B.M., and Lempert N. Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease. Transplant Proc 25 (1993) 1421
4. Sati H.I., Ahya R., and Watson H.G. Incidence and associations of acute renal failure complicating high-dose intravenous immunoglobulin therapy. Br J Haematol 113 (2001) 556
5. Limaye A.P., Corey L., Koelle D.M., et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid organ transplants. Lancet 356 (2000) 645
6. Kazatchine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345 (2001) 747
7. Zikos P., Van Lint M.T., Lamparelli T., et al. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT). Haematologica 83 (1998) 132